Vomiting News and Research

RSS

Vomiting is the process the body uses to eject some or all of the contents of the stomach through the mouth.

Exparel (DepoBupivacaine) shows promise in hernia repair

A Phase II trial of a single intraoperative administration of Exparel (DepoBupivacaine) resulted in significantly reduced pain with activity in the first 8 to 24 hours following surgery, when pain is generally greatest, compared to conventional treatment.

14 Dec 2008

Zometa (zoledronic acid) shown to enhance chemotherapy in reducing breast tumor size

New data released demonstrates that the addition of Zometa (zoledronic acid) injection to standard chemotherapy before breast cancer surgery reduces the size of breast tumors more effectively than chemotherapy alone in women with early-stage disease.

14 Dec 2008

Estrogen therapy can help control metastatic breast cancer

For breast cancer survivors, the idea of taking estrogen pills is almost a taboo. In fact, their doctors give them drugs to get rid of the hormone because it can fuel the growth of breast cancer.

12 Dec 2008

Magnets in toys pose serious health risks

While the danger of magnets for children is increasingly recognized, they don't receive treatment for swallowing them as quickly as needed, and parents don't receive sufficient warning on toys, according to a new study.

10 Dec 2008

New data on ZOLINZA (vorinostat) in combination with Bortezomib

Results from two Phase 1 studies of ZOLINZA (vorinostat), Merck's oral histone deacetylase (HDAC) inhibitor, administered in combination with bortezomib, showed early anti-tumor activity in patients with relapsed and/or refractory multiple myeloma, including those previously treated with and no longer responding to bortezomib.

10 Dec 2008

Merck Serono's Kuvan receives European marketing authorization

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today announced that the European Commission has granted marketing authorization for Kuvan(R) for the treatment of hyperphenylalaninemia (HPA) in phenylketonuria (PKU) or BH4 deficient patients.

10 Dec 2008

Chronic myelogenous leukemia patient survey shows that side effects are a serious issue

Startling findings from a new CML (chronic myelogenous leukemia) patient survey were presented at a satellite meeting of the American Society of Hematology annual meeting, in San Francisco.

8 Dec 2008

Amylin, Lilly update on FDA review of Byetta (exenatide) injection monotherapy submission

Amylin Pharmaceuticals, Inc. and Eli Lilly and Company have announced that the U.S. Food and Drug Administration (FDA) is continuing with its review of the regulatory application for use of Byetta (exenatide) injection as stand-alone therapy (monotherapy) in people with type 2 diabetes who are not achieving acceptable blood sugar control.

8 Dec 2008

Alarm over high lead contamination of Esperance sea food

Alarm over high lead contamination of Esperance sea food. The presence of high concentrations of lead found in fish in a part of Western Australia has prompted a warning to people living in the Esperance area to avoid eating some local seafood.

8 Dec 2008

Interferon as long-term treatment for hepatitis C not effective

Use of the drug interferon as a long-term maintenance strategy to slow the progression of liver disease associated with the hepatitis C virus is ineffective, UT Southwestern Medical Center researchers and their colleagues from nine other institutions have found in a multicenter study.

5 Dec 2008

Acupuncture just as effective without needle penetration

Acupuncture works - but it works equally well with or without needle penetration. This conclusion can be drawn from a treatment study involving cancer patients suffering from nausea during radiotherapy.

1 Dec 2008

Parents of new babies should be considered for a whooping cough booster, say experts

A booster vaccination for parents of new babies and other household members may be the most effective way of preventing the fatal form of whooping cough in young infants, say a group of paediatric intensive care doctors on bmj.com.

28 Nov 2008

Schoolies warned that after-effects of drinking or drug-taking could disguise the start of meningococcal disease

Following reports that an 18-year-old student celebrating 'schoolies' week on Queensland's Gold Coast has been hospitalised with meningococcal disease, health officials have warned schoolies that the after-effects of drinking or drug-taking could disguise the onset of the disease.

26 Nov 2008

Signs of stroke - most people ignorant

A Mayo Clinic study shows a majority of stroke patients don't think they're having a stroke -- and as a result -- delay seeking treatment until their condition worsens.

25 Nov 2008

Tapentadol hydrochloride approved for pain relief

The U.S. Food and Drug Administration has approved Tapentadol hydrochloride, an immediate-release oral tablet for the relief of moderate to severe acute pain.

24 Nov 2008

Neurological health risk in children with blunt head injuries: fashion hair beads

An intriguing article published in the December 2008 online issue of Journal of Neurosurgery: Pediatrics may come as quite a surprise to parents, especially those with little girls.

21 Nov 2008

Reminder, signs of a heart attack can be subtle

You know the drill: join the family for feasting on a high-fat, carbohydrate-filled meal followed by a generous slice of pumpkin pie

21 Nov 2008

FDA approves tapentadol immediate-release tablets for pain in adults

Millions of Americans with moderate to severe acute pain and their health-care providers will soon have a new treatment option.

21 Nov 2008

Ortho Biotech submits NDA for Trabectedin in relapsed ovarian cancer

Ortho Biotech Products, L.P. has announced the submission of a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for trabectedin when administered in combination with DOXIL (doxorubicin HCI liposome injection) for the treatment of women with relapsed ovarian cancer (ROC).

20 Nov 2008

FDA approves Banzel (rufinamide) for Lennox-Gastaut syndrome

The U.S. Food and Drug Administration has approved a new drug, Banzel (rufinamide), for use as an adjunctive (add-on) treatment for seizures associated with Lennox-Gastaut syndrome.

20 Nov 2008